Connect Biopharma Holdings (CNTB) EBT Margin (2024 - 2026)

Connect Biopharma Holdings (CNTB) posted EBT Margin of 11449.7% for Q1 2026, up 89.31% sequentially from 107118.75% in Q3 2025.

Connect Biopharma Holdings (CNTB) EBT Margin (2024 - 2026) Analysis & Trends

Connect Biopharma Holdings has reported EBT Margin for 3 years, with the latest figure at 11449.7% in Q1 2026.

Quarterly EBT Margin changed N/A year-over-year to 11449.7% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 27645.92% (changed N/A YoY) and the FY2025 annual result came in at 86379.69%, down 8632051.0% from the prior year.
EBT Margin advanced to 11449.7% in Q1 2026 per CNTB's latest filing, from 107118.75% in the prior quarter.
Over five years, EBT Margin peaked at 1051.6% in Q3 2024 and troughed at 107118.75% in Q3 2025.
A 3-year average of 29527.83% and a median of 11449.7% in 2026 frame the typical range for EBT Margin.
The widest YoY moves for EBT Margin: up 10606715 bps in 2025, down 10606715 bps in 2025.
Over 3 years, EBT Margin stood at 1260.74% in 2024, then plunged by 8396 bps to 107118.75% in 2025, then jumped by 89 bps to 11449.7% in 2026.
According to Business Quant data, EBT Margin over the past three periods registered 11449.7%, 107118.75%, and 26758.33% for Q1 2026, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	35.61%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	35.71%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-528.97%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	18.33%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	13.77%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-2.67%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	12.09%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-25.06%
10	Connect Biopharma Holdings	144.32 Mn	144.32 Mn	-	-622.25%

Download Data